Cosmo sees FY revenue EUR 102-107m

Cosmo sees FY revenue EUR 102-107m

Cosmo Pharmaceuticals N.V. has revised its fiscal year (FY) revenue forecast to EUR 102-107 million, according to its latest half-year report. This projection reflects the company's strategic initiatives and market performance in the first half of 2025 [3].

The company's mission is to empower patients, healthcare professionals, and partners with life-changing confidence by innovating at the intersection of science and technology. Cosmo Pharmaceuticals' revenue growth is driven by several key products and initiatives. The GI Genius™ platform, a real-time AI-powered endoscopy solution, has seen significant expansion with the addition of the Intelligent Tablet and integration with Apple Vision Pro, GI Genius™ XR [3].

Cosmo Pharmaceuticals' Derma Winlevi® topical acne treatment remains the number one branded product in the U.S., with over 1.4 million prescriptions since its launch in November 2021. The product's global expansion is evident in its presence in Canada, Australia, and the United Kingdom, with recent commercial launches in Singapore and Malaysia. Regulatory approvals in Jordan and Mexico, along with anticipated approvals from the European Medicines Agency, further bolster its global reach [3].

The company's strong performance in the generic market is also notable. Products such as Rifamycin® and Eleview® have shown solid year-on-year growth, partially offsetting broader market declines due to generic competition. In the Japanese market, Lialda®/Mezavant®/Mesavancol®/Mesalamine Lialda® revenues grew by 27.3% and 199% respectively, while Mezavant® revenues increased by 7.8% [3].

Cosmo Pharmaceuticals' commitment to sustainability and ethical business conduct is evident in its recent milestones. The company's MSCI ESG Rating has been upgraded from BBB to A, and it has entered the top 100 of its LSEG ESG-rated peer group, ranked #42. Additionally, Cosmo Pharmaceuticals has obtained integrated certification for ISO 14001, ISO 45001, and ISO 50001, reflecting its commitment to quality, sustainable operations, and employee wellbeing [3].

These developments underscore Cosmo Pharmaceuticals' strategic focus on innovation, market expansion, and sustainable operations, which are expected to drive its revenue growth in the coming fiscal year.

References:
[1] https://www.tipranks.com/news/company-announcements/cosmo-energy-announces-share-split-and-dividend-forecast-revision
[2] https://finance.yahoo.com/news/costar-raises-annual-revenue-forecast-210626856.html
[3] https://www.marketscreener.com/news/cosmo-pharmaceuticals-n-half-year-report-2025-ce7c5cddde8cfe26